Trial Profile
A Phase 1/2, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs LBS 007 (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; First in man
- Sponsors Lin Bioscience
- 30 Jul 2023 Status changed from not yet recruiting to recruiting.
- 23 Feb 2023 Status changed from planning to not yet recruiting.
- 24 Apr 2018 According to a Lin Bioscience media release, this trial is expected to initiate in Q4 of 2018.